Scarica l'app Stockscreener
1.45
2.84%
0.04
Dopo l'orario di chiusura:
1.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.41
Aprire:
$1.43
Volume 24 ore:
733.07K
Relative Volume:
0.89
Capitalizzazione di mercato:
$163.50M
Reddito:
$27.08M
Utile/perdita netta:
$-37.00M
Rapporto P/E:
-2.7885
EPS:
-0.52
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
-11.04%
1M Prestazione:
+0.69%
6M Prestazione:
-41.53%
1 anno Prestazione:
+27.19%
Intervallo 1D:
$1.39
$1.52
Intervallo di 1 settimana:
$1.3801
$1.655
Portata 52W:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Confronta ACRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.45 | 163.50M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | Wedbush | Outperform |
| 2025-03-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Consensus Price Target from Analysts - Defense World
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26% - simplywall.st
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline By Investing.com - Investing.com South Africa
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline - Investing.com Australia
Bank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Vitiligo Drugs Market Exclusive Report with Detailed Study Analysis | Dermavant Sciences, Aclaris Therapeutics - newstrail.com
H.C. Wainwright maintains Buy on Aclaris stock, $16 target By Investing.com - Investing.com Canada
Aclaris Therapeutics Approves 2025 Equity Incentive Plan - TipRanks
Aclaris Therapeutics at Jefferies Conference: Strategic Pipeline Advances By Investing.com - Investing.com Canada
Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 - MSN
Transcript : Aclaris Therapeutics, Inc. Presents at H.C. Wainwright ?HCW@Home? series, May-16-2025 01 - marketscreener.com
Aclaris begins phase 2 trial for atopic dermatitis drug By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com
Aclaris begins phase 2 trial for atopic dermatitis drug - Investing.com Australia
Aclaris Therapeutics (ACRS) Begins Phase 2 Trial for Atopic Dermatitis Treatment | ACRS Stock News - GuruFocus
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Two Sigma Investments LP Sells 68,646 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Northern Trust Corp Has $434,000 Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - MSN
What is Wedbush’s Forecast for ACRS Q2 Earnings? - Defense World
Millennium Management LLC Decreases Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at Wedbush - Defense World
Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewswire
Aclaris Therapeutics Secures Double Speaking Slots at Major June Healthcare Conferences - Stock Titan
Wedbush sets Aclaris stock Outperform with $8 target By Investing.com - Investing.com India
Wedbush Initiates Coverage of Aclaris Therapeutics (ACRS) with Outperform Recommendation - Nasdaq
Aclaris Therapeutics (ACRS) Receives Outperform Rating from Wedbush | ACRS Stock News - GuruFocus
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbush | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Positive Rating from Wedbus - GuruFocus
Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target - marketscreener.com
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbu - GuruFocus
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - The Globe and Mail
Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla) - The Globe and Mail
Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $10.00 - Defense World
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
HC Wainwright Has Positive Forecast for ACRS Q3 Earnings - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP - Defense World
Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Reduced by Price T Rowe Associates Inc. MD - Defense World
Aclaris Therapeutics (ACRS) Price Target Update by HC Wainwright & Co. | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus
Aclaris Therapeutics Reports Q1 2025 Financial Results - MSN
Androgenetic alopecia Pipeline 2025: Groundbreaking Clinical - openPR.com
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN
Scotiabank Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price - Defense World
Aclaris Therapeutics (ACRS) Price Target Lowered by Scotiabank | - GuruFocus
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aclaris Therapeutics Inc Azioni (ACRS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):